"Is Akkermansia safe?" is the question every R&D and regulatory team has to answer before any other question matters. It is also a question with an unusual property in the probiotic world: the honest answer is not "it has been eaten for decades" — Akkermansia muciniphila has no long history of food use. It is a next-generation organism whose safety case has to be built from published evidence, study by study.
That is actually good news for a diligent buyer. A safety case built on documented toxicology is one you can read, check, and audit. This article lays out what the published safety record for AKK PROBIO (strain CGMCC No.20955) contains — genotoxicity, acute and sub-chronic toxicity, antibiotic-resistance and virulence screening, the NOAEL figure, and the human data — and how to read it.
Quick Answer
Published safety evidence on AKK PROBIO covers the standard modern probiotic safety battery, and the results are uniformly negative for adverse findings: no mutagenic or clastogenic activity in standard genotoxicity assays; no treatment-related abnormalities in acute and sub-chronic toxicity studies, even at very high doses; genome screening found no concerning virulence profile, and the strain's natural moxifloxacin resistance was shown not to transfer. From these data the authors concluded a NOAEL of 9.2×10⁹ cells/kg body weight/day in the 90-day study, corresponding to 6.4×10¹¹ viable bacteria per day for a 70 kg adult — roughly 640 billion cells, well above formulated use levels (Ma et al., Foods 2024, PMID: 38338577). Human studies on the strain, including a 130-subject RCT, reported no safety concerns. "Safe" here means precisely this: safety documented in published, citable studies under defined conditions — not an absolute guarantee, and not a claim about populations or doses outside the studied conditions.
Why a Next-Generation Organism Needs a Different Safety File
For legacy probiotics — common Lactobacillus or Bifidobacterium strains — decades of fermented-food consumption provide a background safety assumption. Akkermansia muciniphila was only isolated in 2004, and it enters the food supply through deliberate formulation, not culinary tradition. Regulatory frameworks reflect this: a next-generation organism needs a purpose-built dossier, evaluated on its own data.
For buyers, this changes what "good" looks like. The question is not "how long has it been eaten?" but "how complete is the published safety package, and does it cover the exact strain I am buying?" Genus- or species-level reassurance is not transferable; the dossier must be strain-specific.
The Strain-Level Safety Package
The core strain-specific safety publication for AKK PROBIO is Ma et al., Foods (2024) — a characterization and preliminary safety evaluation of CGMCC No.20955, available in full text (PMC10855611). Its components, and what each showed:
Genotoxicity. The strain was tested in the standard battery — a bacterial reverse mutation (Ames) assay and an in vitro mammalian cell micronucleus assay. Results were negative for mutagenic and clastogenic activity, even at exceedingly high doses (in vitro studies).
Acute and sub-chronic toxicity. Animal studies found no treatment-related adverse effects — no hematological or histopathological abnormalities — during acute and sub-chronic administration (Preclinical; animal study).
Antibiotic resistance and gene transfer. The strain's drug-resistance profile was characterized at the genome level. A. muciniphila PROBIO is naturally resistant to moxifloxacin; critically, in vitro conjugation experiments showed this resistance does not transfer — the property that matters for safety assessment is not whether a resistance exists, but whether it can move to other organisms.
Genome-based screening. Whole-genome analysis annotated only three potential drug-resistance genes and one virulence-factor gene — a clean profile for a candidate food organism.
Gastrointestinal tolerance. The strain showed superior gastrointestinal tolerance in characterization testing — relevant because an organism intended for oral use must survive the passage it is designed for.
The NOAEL Number, in Context
NOAEL — no-observed-adverse-effect level — is the highest exposure at which no adverse effects were observed in the toxicology studies. For AKK PROBIO, Ma et al. concluded a NOAEL of 9.2×10⁹ cells/kg body weight/day in the 90-day study — 6.4×10¹¹ viable bacteria per day for an average 70 kg adult, about 640 billion cells.
The useful way to read this number is as a margin. Formulated use levels for Akkermansia products are typically in the tens-of-billions range per day; the regulatory conditions of use for AKK PROBIO's pasteurized form under NDI #1468 are 3.4×10¹⁰ TFU/day. The NOAEL sits roughly an order of magnitude above the highest of those — which is what a safety margin is supposed to look like.
The Human Layer
Toxicology establishes the margin; human studies establish tolerability in practice. For AKK PROBIO, the human record includes a 130-subject, 8-week, randomized, double-blind, placebo-controlled trial in overweight adults testing both live and pasteurized forms, with no safety concerns reported (DOI: 10.26599/FSHW.2025.9250659). At the species level, an earlier proof-of-concept human study of pasteurized A. muciniphila in overweight and obese volunteers likewise reported good safety and tolerability (Depommier et al., Nature Medicine 2019, PMID: 31263284).
One caution we apply to our own reading, and recommend to yours: when reviewing "Akkermansia safety" literature, check whose strain and whose formulation each study used. Some widely cited toxicology on this species was conducted on other companies' formulations. That work is useful species-level context, but it is not part of AKK PROBIO's strain-specific file — and we do not cite it as such.
What This Does — and Does Not — Establish
Published toxicology with a defined NOAEL is the strongest form of safety documentation an ingredient can have — and it is still bounded. Three bounds to keep in view:
Populations. The regulatory conditions of use exist precisely because some groups were not studied: NDI #1468 covers healthy adults 18 and over, and excludes pregnant and lactating women. The safety file does not speak to those populations, and neither should your product.
Doses. The NOAEL defines a ceiling observed in studies, not a license for arbitrary formulation. Staying within the studied and notified use levels is what keeps the safety case attached to your product.
Individual variation. Published studies characterize populations on average. A documented safety profile is not a promise that no individual will ever report an adverse experience — it is the audited, citable foundation on which a responsible brand's safety monitoring stands.
Request the Safety Dossier
Every element above resolves to a document: the Ma et al. full text, the RCT publication, the GRAS expert-panel conclusion under 21 CFR §170.30, and the NDI acknowledgment. If your QA and regulatory teams are evaluating Akkermansia for a launch, we will provide the complete safety and regulatory package for their review. Request a sample or begin with the public summaries on our Regulatory & Safety page.